Novo Nordisk Teams with Form Health, 9amHealth for Obesity Care

Novo Nordisk has selected two providers — Form Health and 9amHealth — to offer obesity care for patients who access Wegovy (semaglutide) and Saxenda (liraglutide) through its direct-to-patient NovoCare platform.

“Obesity and related cardiometabolic conditions require more than a prescription; they demand comprehensive, reliable care,” Florencia Halperin, M.D., MMSc, chief medical officer of Form Health, said in a news release.

Form Health’s care team includes a certified physician, advanced practice providers and registered dietitians with specialized training in obesity treatment. They can develop individualized treatment plans that address behavioral health, nutrition and physical activity, as well as prescriptions for weight loss medications.

“We’re in the midst of a once-in-a-lifetime shift driven by next-generation obesity medications,” Paul Geevarghese, Pharm.D., co-founder and chief operating officer at 9amHealth, said in a separate news release. “People with chronic cardiometabolic conditions are proactively seeking medical care in unprecedented numbers, which creates the opportunity to deliver diagnostics, prevention, lifestyle support, and treatment in one seamless virtual experience.”

9amHealth is a virtual provider offering medical evaluations, at-home lab testing, personalized nutrition guidance, ongoing support and prescriptions for weight loss medications. medications.

Related: FDA Grants Accelerated Approval of Wegovy to Treat Liver Disease

The FDA initially approved Wegovy in 2021 to help adults with obesity to lose weight. The indication was expanded in 2022 to include children aged 12 years and older with obesity. Wegovy was approved to reduce the risk of major cardiovascular events in 2024 and granted accelerated approval just last week to treat patients with metabolic dysfunction-associated steatohepatitis (MASH).

Wegovy has a list price of $1,349; the company says that 90% of patients with commercial insurance have a co-pay of $0 to $25 per month. For self-pay patients, Novo Nordisk offers Wegovy at $499 per month through NovoCare.

In 2024, sales of Wegovy and Novo Nordisk’s other semaglutide products (Ozempic and Rybelsus, which both treat type 2 diabetes) increased 27% to $39.4 billion. Sales of Wegovy alone grew 57% to $9.4 billion.

The three semaglutide drugs are at the top of CMS's next 15 Medicare Part D drugs to be subject to price negotiations as part of the Inflation Reduction Act. The new prices will become effective in 2027. The three semaglutide products had total Part D gross costs of $14.4 billion from November 2023 to October 2024, according to the CMS.

NovoCare also provides patient support and access or savings to other Novo Nordisk products such as:

• diabetes products, including Ozempic, Rybelsus and Victoza (liraglutide), and its insulins, including Fiasp, Novolog, Novo Pen and Tresiba
• growth-related disorder products, including Norditropin (somatropin) and Sogroya (somapacitan-beco)
• bleeding disorder products, including Alhmeo (concizumab-mtci), NovoSeven RT (coagulation factor VIIa), NovoEight (antihemophilic factor) and Rebinyn (coagulation factor IX).

Novo Nordisk is awaiting FDA approval for a once-daily, 25 mg oral formulation of Wegovy for adults living with obesity and to reduce the risk of major adverse cardiovascular events (MACE) in adults who are overweight or have obesity and an established cardiovascular disease. A decision is expected in December 2025.